By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron Pharmaceuticals, Inc.
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





Company News
Regeneron Pharmaceuticals, Inc. (REGN) R&D Chief Reveals Allergy Drug May Be Darling Of Its Pipeline 9/19/2014 3:48:18 PM
Kymab Succeeds In Revoking Regeneron Pharmaceuticals, Inc. (REGN)’s European Patent 9/19/2014 10:14:54 AM
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA 9/16/2014 5:40:19 AM
Regeneron Pharmaceuticals, Inc. (REGN) Executive Outlines Strategy For Avoiding Affordable Care Act Penalties 9/15/2014 6:20:37 AM
Regeneron Pharmaceuticals, Inc. (REGN) Announces Submission Of Application For EYLEA® (Aflibercept) Injection In Japan For Macular Edema Following Branch Retinal Vein Occlusion 9/4/2014 11:22:48 AM
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/2/2014 6:27:22 AM
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014 8:04:35 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Ring The NASDAQ Stock Market Opening Bell 8/20/2014 7:32:11 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Ring The NASDAQ Stock Market Opening Bell 8/19/2014 10:34:59 AM
Regeneron Pharmaceuticals, Inc. (REGN) Announces Upcoming 2014 Investor Conference Presentations 8/19/2014 8:23:10 AM
12345678910...
//-->